{"generic":"Pneumococcal 13-Valent Vaccine, Diphtheria Conjugate","drugs":["Pneumococcal 13-Valent Vaccine, Diphtheria Conjugate","Prevnar 13"],"mono":{"0":{"id":"jxa1s0","title":"Generic Names","mono":"Pneumococcal 13-Valent Vaccine, Diphtheria Conjugate"},"1":{"id":"jxa1s1","title":"Dosing and Indications","sub":{"0":{"id":"jxa1s1b4","title":"Adult Dosing","mono":"<b>Pneumococcal vaccination, 13-valent conjugate vaccine:<\/b> (50 years or older) administer 1 dose IM (manufacturer dosing) "},"1":{"id":"jxa1s1b5","title":"Pediatric Dosing","mono":"<ul><li>administer pneumococcal 13-valent vaccine prior to administration of pneumococcal 23-valent vaccine.<\/li><li><b>usual dose:<\/b> 4-dose series IM at age 2, 4, 6, and 12 to 15 months; for catch-up immunization, the number of doses depends on age of first vaccination; minimum age to vaccinate is 6 weeks<\/li><li><b>Pneumococcal vaccination, 13-valent conjugate vaccine:<\/b> (primary series) 1 dose IM for 4 doses at 2, 4, 6, and 12 to 15 months old<\/li><li><b>Pneumococcal vaccination, 13-valent conjugate vaccine:<\/b> (unvaccinated, 7 to 11 months) 1 dose IM for 3 doses; administer dose 1 and 2 at least 4 weeks apart, and dose 3 after first birthday and at least 2 months after dose 2<\/li><li><b>Pneumococcal vaccination, 13-valent conjugate vaccine:<\/b> (unvaccinated, 12 to 23 months), 1 dose IM for 2 doses; administer at least 2 months apart<\/li><li><b>Pneumococcal vaccination, 13-valent conjugate vaccine:<\/b> (unvaccinated, 24 to 71 months) 1 dose IM<\/li><li><b>Pneumococcal vaccination, 13-valent conjugate vaccine:<\/b> (6 years or older) 1 dose IM; if previously vaccinated with pneumococcal 7-valent or 13-valent vaccine, allow 8 weeks to elapse before vaccination<\/li><li><b>Pneumococcal vaccination, 13-valent conjugate vaccine:<\/b> (completely immunized with pneumococcal 7-valent vaccine; 15 to 71 months) 1 dose IM; allow 8 weeks to elapse from last dose of pneumococcal 7-valent vaccine before vaccination<\/li><\/ul>"},"3":{"id":"jxa1s1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Pneumococcal vaccination, 13-valent conjugate vaccine<br\/>"}}},"3":{"id":"jxa1s3","title":"Contraindications\/Warnings","sub":[{"id":"jxa1s3b9","title":"Contraindications","mono":"allergic reactions, severe (eg, anaphylaxis), to any component of the vaccine or diphtheria toxoid <br\/>"},{"id":"jxa1s3b10","title":"Precautions","mono":"<ul><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>apnea has been observed in some premature infants following vaccine administration<\/li><li>does not replace use of 23-valent pneumococcal vaccine in high-risk children 24 months and older or in geriatrics<\/li><li>for intramuscular use only<\/li><li>impaired immune responsiveness; reduced antibody response<\/li><li>will not protect against streptococcus pneumoniae disease other than that caused by the seven serotypes included in the vaccine, nor will it protect against other microorganisms that cause invasive infection such as bacteremia and meningitis<\/li><\/ul>"},{"id":"jxa1s3b11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"jxa1s3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jxa1s4","title":"Drug Interactions","sub":{"1":{"id":"jxa1s4b14","title":"Major","mono":"<ul><li>Acetaminophen (probable)<\/li><li>Cyclosporine (theoretical)<\/li><\/ul>"}}},"5":{"id":"jxa1s5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (pediatrics, 24.3% to 42.9%; adults, 10.8% to 20.2%), Injection site pain (adults, 51% to 88.8%), Swelling at injection site (pediatrics, 19.6% to 37.6%; adults, 10% to 21.7%), Tenderness (pediatrics, 47.3% to 89%.)<\/li><li><b>Gastrointestinal:<\/b>Decrease in appetite (pediatrics, 22.9% to 51%; adults, 10.4% to 25.3%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia, Aggravated (adults, 9.7% to 25.6%), Arthralgia, New onset (adults, 12.6% to 31.5%), Difficulty moving arm (adults, 10.5% to 40.7%), Myalgia, Aggravated (adults, 12.3% to 39.9%), Myalgia, New onset (adults, 25.3% to 61.8%)<\/li><li><b>Neurologic:<\/b>Decreased sleep (pediatrics, 5.7% to 46.5%), Headache (adults, 23.7% to 65.9%), Hypersomnia (pediatrics, 18.8% to 71.5%)<\/li><li><b>Psychiatric:<\/b>Irritability (pediatrics, 25.2% to 85.6%)<\/li><li><b>Other:<\/b>Fatigue (adults, 34% to 63.3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Gastroenteritis (pediatrics, 0.9%)<\/li><li><b>Neurologic:<\/b>Seizure (pediatrics, less than 1%)<\/li><li><b>Respiratory:<\/b>Bronchiolitis (pediatrics, 0.9%), Pneumonia (pediatrics, 0.9%)<\/li><li><b>Other:<\/b>Sudden infant death syndrome (0.063%)<\/li><\/ul>"},"6":{"id":"jxa1s6","title":"Drug Name Info","sub":{"0":{"id":"jxa1s6b17","title":"US Trade Names","mono":"Prevnar 13<br\/>"},"2":{"id":"jxa1s6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jxa1s6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jxa1s7","title":"Mechanism Of Action","mono":"The pneumococcal 13-valent diphtheria conjugate vaccine, consisting of polysaccharides attached to a nontoxic diphtheria carrier protein, causes a T-cell dependent immune response which signals the maturation of B-cells to produce antibodies and memory cells to pneumococcal polysaccharides.<br\/>"},"9":{"id":"jxa1s9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>do not give IV, intradermally, or subQ<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>shake well to maintain homogenous suspension of adjuvant component; do not use if adjuvant cannot be resuspended<\/li><li>do not mix with other vaccines or agents in the same syringe<\/li><li>administer IM; inject into the anterolateral aspect of the thigh (infants) or deltoid muscle (toddlers, young children, adults); do not inject in the gluteal area or in areas of major nerve trunks and\/or blood vessels<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jxa1s10","title":"Monitoring","mono":"No specific monitoring has been determined.<br\/>"},"13":{"id":"jxa1s13","title":"Clinical Teaching","mono":"This drug may cause injection site reaction, decreased appetite, diarrhea, vomiting, irritability, restless sleep, or fever.<br\/>"}}}